Literature DB >> 24373987

Hypocretin in cerebrospinal fluid is positively correlated with Tau and pTau.

Michael Deuschle1, Claudia Schilling2, F Markus Leweke2, Frank Enning2, Thomas Pollmächer3, Hermann Esselmann4, Jens Wiltfang5, Lutz Frölich2, Isabella Heuser6.   

Abstract

It has been suggested that sleep-wake regulation as well as hypocretins play a role in the pathophysiology of Alzheimer's disease. We analyzed Aβ40, Aβ42, Tau protein, phosphorylated Tau (pTau) protein as well as hypocretin-1 concentrations in the CSF of a detection sample of 10 patients with Alzheimer's disease (AD) as well as 10 age- and gender-matched patients with major depression as a comparison group of different pathology. In order to replicate the findings, we used a confirmation sample of 17 AD patients and 8 patients with major depression. We found hypocretin-1 concentrations in CSF not to differ between patients with depression and AD. However, hypocretin-1 was significantly related to Tau (r=0.463, p<0.001) and pTau (r=0.630, p<0.0001). These effects were more pronounced in depressed patients when compared to AD patients. We conclude that hypocretin-1 may play a role in the metabolism of Tau proteins across different diagnostic entities including AD. It has to be determined whether there is a causal relationship between hypocretin-1 and Tau as well as pTau.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Aβ; Depression; Hypocretin; Orexin; Tau protein

Mesh:

Substances:

Year:  2013        PMID: 24373987     DOI: 10.1016/j.neulet.2013.12.036

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  8 in total

Review 1.  Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease?

Authors:  Bryce A Mander; Joseph R Winer; William J Jagust; Matthew P Walker
Journal:  Trends Neurosci       Date:  2016-06-17       Impact factor: 13.837

Review 2.  The sleep-wake cycle and Alzheimer's disease: what do we know?

Authors:  Miranda M Lim; Jason R Gerstner; David M Holtzman
Journal:  Neurodegener Dis Manag       Date:  2014

3.  Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects.

Authors:  Ricardo S Osorio; Emma L Ducca; Margaret E Wohlleber; Emily B Tanzi; Tyler Gumb; Akosua Twumasi; Samuel Tweardy; Clifton Lewis; Esther Fischer; Viachaslau Koushyk; Maria Cuartero-Toledo; Mohammed O Sheikh; Elizabeth Pirraglia; Henrik Zetterberg; Kaj Blennow; Shou-En Lu; Lisa Mosconi; Lidia Glodzik; Sonja Schuetz; Andrew W Varga; Indu Ayappa; David M Rapoport; Mony J de Leon
Journal:  Sleep       Date:  2016-06-01       Impact factor: 5.849

4.  Cerebrospinal Fluid Hypocretin and Nightmares in Dementia Syndromes.

Authors:  Lynn Marie Trotti; Donald L Bliwise; Glenda L Keating; David B Rye; William T Hu
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2021-02-16

5.  Orexin-A in Patients With Lewy Body Disease: A Systematic Review and Meta-Analysis.

Authors:  Jinghuan Gan; Zhichao Chen; Jiuyan Han; Lingyun Ma; Shuai Liu; Xiao-Dan Wang; Yong Ji
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-17       Impact factor: 5.555

6.  Cerebrospinal fluid orexin in Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Spencer P Treu; David T Plante
Journal:  Sleep Med       Date:  2021-07-13       Impact factor: 4.842

7.  Orexin receptors exert a neuroprotective effect in Alzheimer's disease (AD) via heterodimerization with GPR103.

Authors:  Julie Davies; Jing Chen; Ryan Pink; David Carter; Nigel Saunders; Georgios Sotiriadis; Bo Bai; Yanyou Pan; David Howlett; Annette Payne; Harpal Randeva; Emmanouil Karteris
Journal:  Sci Rep       Date:  2015-07-30       Impact factor: 4.379

Review 8.  Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies.

Authors:  Elena Urrestarazu; Jorge Iriarte
Journal:  Nat Sci Sleep       Date:  2016-01-14
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.